Singapore Institute of Advanced Medicine Holdings (SAM) Partners with Perspectum to Expand CoverScan Multi-Organ Health Assessment in SingaporeProgram for the expansion of quantitative, non-invasive MRI assessment of multiple organs to preventive health services in Singapore

OXFORD, U.K. and SINGAPORE – AUGUST 06, 2026 – Perspectum, a precision health company that delivers non-invasive solutions to accelerate drug development and improve patient outcomes in metabolic disease, today announced with Singapore Institute of Advanced Medicine Holdings Ltd (“SAM”), a Singapore Exchange-listed integrated healthcare provider, a program delivered through its Advanced Medicine Imaging (AMI) subsidiary, a leading diagnostic imaging provider in Singapore, to offer CoverScan, Perspectum’s multi-organ MRI assessment to patients in Singapore.

Chronic conditions affecting the liver, heart, kidneys, and pancreas often develop silently and together, yet health assessments typically examine organs in isolation. As demand for preventive and personalized healthcare grows across Asia, clinicians and patients are seeking a more complete picture of health from a single, non-invasive assessment.

CoverScan is an MRI-based solution that quantifies the health of these organs in a single, non-contrast MRI scan; measuring 1) liver disease activity and fat, 2) structure and function of the heart, 3) visceral and pancreas fat, and 4) inflammation and fibrosis of the pancreas and kidneys. Using a cloud-based delivery model, CoverScan generates a unified, quantitative report that provides a view of systemic health and a digital profile of an individual’s metabolic risk, consolidating multi-organ assessment into a single scan and report to help coordinate care.

SAM’s AMI team will deliver CoverScan at its Singapore clinic, with reports reviewed alongside AMI’s physicians to support patient care and health screening pathways. This partnership marks the first step in a longer-term collaboration between Perspectum and SAM to expand access to quantitative multi-organ health assessment in the region.

“At SAM, our vision is to deliver precision medicine through advanced diagnostics and early disease detection. Introducing CoverScan complements our advanced imaging capabilities, enabling clinicians to assess multiple organs quantitatively from a single MRI examination. This pilot is an important step towards advancing world-class preventive imaging and healthcare in Singapore.”

Paul Yeo, Chief Operating Officer, Singapore Institute of Advanced Medicine Holdings Ltd (SAM).

“Singapore is at the forefront of preventive healthcare, and AMI shares our vision of making comprehensive, non-invasive health assessment accessible to more people. By quantifying the health of multiple organs in a single scan, CoverScan helps clinicians detect and monitor disease earlier, when there is the greatest opportunity to act.”

Dr Rexford Newbould, Chief Operating Officer, Perspectum.

About Perspectum

Perspectum is a global medical technology company developing advanced imaging solutions that support earlier diagnosis and personalized care for patients with metabolic, liver, multi-organ and oncological conditions. Operating across the UK, Europe, Singapore, and US, Perspectum combines biomedical science, clinical expertise and quantitative imaging analytics to help clinicians detect disease sooner and make more informed decisions about patient care. 

For additional information, please visit perspectum.com.

About Singapore Institute of Advanced Medicine Holdings Ltd (SAM)

Singapore Institute of Advanced Medicine Holdings Ltd (“SAM”) is a Singapore Exchange-listed integrated healthcare provider focused on advanced diagnostics, precision medicine and cancer care. Through its subsidiaries, SAM provides diagnostic imaging, nuclear medicine, theranostics, radiation therapy, proton therapy, primary healthcare and preventive health services.

Media contact:

Amanda Chin, SVP Investor Relations

Perspectum · amanda.chin@perspectum.com